Litaba

NEW DELHI, Phuptjane 22 (Xinhua) — Covaxin ea moetsi oa liente oa India oa Bharat Biotech e bontšitse katleho ea liperesente tse 77.8 litekong tsa mohato oa III, ho tlalehiloe mecha ea litaba e mengata ea lehae ka Labobeli.

Tlaleho e itse, "Covaxin ea Bharat Biotech e sebetsa hantle ka liphesente tse 77.8 ho sireletseng khahlanong le COVID-19, ho latela lintlha tse tsoang litekong tsa mohato oa III tse entsoeng ho barupeluoa ba 25,800 ho pholletsa le India."

Sekhahla sa katleho se hlahile ka Labobeli kamora hore komiti ea litsebi tsa sehlooho (SEC) ea Molaoli oa Lithethefatsi Kakaretso oa India (DCGI) e kopane 'me e buisane ka liphetho.

Khamphani ea meriana e ne e rometse lintlha tsa teko ea mohato oa III bakeng sa ente ho DCGI mafelo-bekeng.

Litlaleho li boletse hore khamphani e lebelletsoe ho tšoara seboka sa "pele ho nehelano" le balaoli ba Mokhatlo oa Lefatše oa Bophelo ka Laboraro, ho buisana ka litataiso tsa ho nehelana ka lintlha le litokomane tse hlokahalang qetellong.

India e qalile ho enta batho ba bangata khahlanong le COVID-19 ka la 16 Pherekhong ka ho fana ka liente tse peli tse entsoeng India, e leng Covishield le Covaxin.

Serum Institute of India (SII) e etsa Covishield ea AstraZeneca-Oxford University, ha Bharat Biotech e sebelisane le Lekhotla la India la Lipatlisiso tsa Bongaka (ICMR) ho hlahiseng Covaxin.

Ente ea Sputnik V e entsoeng Russia le eona e ile ea phatlalatsoa naheng eo.